摘要
目的研究产超广谱β-内酰胺酶(ESBLs)大肠埃希菌的医院感染分布及其耐药性。方法选择2019年1月至2020年6月梅州市中医医院320例门诊及院内所收集的痰液、尿液、血液等标本,共检测出大肠埃希菌320株,记录产ESBLs大肠埃希菌的检出率,分析其分布特点及耐药性。结果320株大肠埃希菌中,产ESBLs大肠埃希菌检出株数总计135株,所占比例为42.19%,主要分布于烧伤科、泌尿外科及脑外科,分别占17.78%、17.04%、14.07%;年龄≥60岁的患者产ESBLs大肠埃希菌检出率为53.45%,明显高于年龄<60岁患者的35.78%,且不同标本的产ESBLs大肠埃希菌分布比较差异均有统计学意义(P<0.05);产ESBLs大肠埃希菌对头孢曲松、头孢唑啉、头孢噻肟、环丙沙星、左氧氟沙星、氨曲南、庆大霉素、妥布霉素、头孢吡肟、头孢他啶、哌拉西林/他唑巴坦的耐药率分别为100.00%、100.00%、98.52%、75.56%、77.04%、64.44%、76.30%、31.85%、31.11%、28.89%、5.19%,明显高于非产ESBLs大肠埃希菌的71.35%、76.22%、68.11%、52.97%、54.05%、32.97%、59.46%、17.85%、15.68%、16.22%、0.54%,差异均有统计学意义(P<0.05)。结论产ESBLs大肠埃希菌感染的发病率、耐药情况严峻,临床上应针对药敏结果选择合适的抗生素治疗。
Objective To study the distribution of nosocomial infection due to extended spectrumβ-lactamases(ESBLs)-producing Escherichia coli and drug resistance of the strain.Methods A total of 320 specimens of the sputum,urine,blood,etc from Meizhou Hospital of Traditional Chinese Medicine from January 2019 to June 2020 were selected.A total of 320 strains of Escherichia coli were detected.The detection rate of ESBLs-producing Escherichia coli was recorded,and its distribution characteristics and drug resistance were analyzed.Results In 320 strains of Escherichia coli,135 strains of ESBLs-producing Escherichia coli were detected,accounting for 42.19%,which were mainly distributed in Department of Burn,Department of Urology,and Department of Brain Surgery,accounting for 17.78%,17.04%,and 14.07%respectively.The detection rate of ESBLs-producing Escherichia coli was 53.45%in patients over 60 years of age,which was significantly higher than 35.78%in patients younger than 60 years old,and there were significant differences in the distribution of ESBLs-producing Escherichia coli in different samples(P<0.05).The resistance rates of ESBLs-producing Escherichia coli to ceftriaxone,cefazolin,cefotaxime,ciprofloxacin,levofloxacin,aztreonam,gentamicin,tobramycin,cefepime,ceftazidime,piperacillin/tazobactam were 100.00%,100.00%,98.52%,75.56%,77.04%,64.44%,76.30%,31.85%,31.11%,28.89%,and 5.19%,which were significantly higher than 71.35%,76.22%,68.11%,52.97%,54.05%,32.97%,59.46%,17.85%,15.68%,16.22%,and 0.54%of non-ESBLs-producing Escherichia coli(P<0.05).Conclusion The incidence rate and drug resistance of ESBLs-producing Escherichia coli are severe,and it is necessary to select suitable antibiotics for clinical sensitivity.
作者
李苑芳
谢桂扬
LI Yuan-fang;XIE Gui-yang(Department of Laboratory Medicine,Meizhou Hospital of Traditional Chinese Medicine,Meizhou 514000,Guangdong,CHINA)
出处
《海南医学》
CAS
2021年第10期1279-1282,共4页
Hainan Medical Journal
关键词
大肠埃希菌
产超广谱Β-内酰胺酶
感染
抗生素
耐药性
Escherichia coli
Extended spectrumβ-lactamases
Infection
Antibiotics
Drug resistance
